Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama backed the round as demand for weight loss tools grows
GettyImages/Tatsiana Volkava
Signos Inc. announced a $20 million funding round on Wednesday, with backing from GV (Google $GOOGL Ventures), Dexcom, and Blue Cross Blue Shield of Alabama, alongside a new distribution deal that will make the startup's subscription plans available on Dexcom's direct-to-consumer website.
Signos was founded to improve metabolic health using technology. The company created an AI-powered glucose monitoring platform for weight management and became the first in its category to receive FDA clearance in 2025. The system uses a Dexcom biosensor to track glucose levels, then analyzes data related to eating, rest, and stress to provide personalized advice for healthier habits.
As part of the expanded partnership, Signos will be sold through Stelo.com, Dexcom's direct-to-consumer site. Dexcom also participated in the funding round. "Signos has developed a system that translates glucose biosensing data into actionable insights for people focused on weight management," said Jon Coleman, Dexcom's chief commercial officer, in a statement. "Making Signos available on Stelo.com is a natural next step."
Among the planned uses for the new investment is a build-out of predictive AI capabilities, including a meal-scoring function that draws on individual user history to assess potential glucose impact before a person eats, according to CNBC.
Tenfold growth in both revenue and the user base over the prior six months was cited by Fouladgar-Mercer, who stopped short of providing actual numbers. He told CNBC that "tens of thousands" of users have participated in clinical studies. The company also declined to share its valuation following the round.
Fouladgar-Mercer told CNBC that Signos is built to serve two distinct user types: people already taking GLP-1 medications who want additional metabolic insight, and those pursuing weight loss without pharmaceutical intervention. "The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data," he said in a statement.
Blue Cross Blue Shield of Alabama invested through its 450 Ventures vehicle, a signal the company said reflects growing interest among health insurers in metabolic health tools as GLP-1 drug costs place pressure on payer budgets. Signos was founded in 2018.
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
